Research Papers:

FAK Inhibition with Small Molecule Inhibitor Y15 Decreases Viability, Clonogenicity, and Cell Attachment in Thyroid Cancer Cell Lines and Synergizes with Targeted Therapeutics

Shalana O’Brien _, Vita M. Golubovskaya, Jeffrey Conroy, Song Liu, Dan Wang, Biao Liu and William G. Cance

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2014; 5:7945-7959. https://doi.org/10.18632/oncotarget.2381

Metrics: PDF 3845 views  |   HTML 3408 views  |   ?  


Shalana O’Brien1,2, Vita M. Golubovskaya1, Jeffrey Conroy3, Song Liu4, Dan Wang4, Biao Liu4, William G. Cance1

1 Department of Surgical Oncology; Roswell Park Cancer Institute, Buffalo, NY

2 University at Buffalo/State University of New York, Buffalo, NY

3 Genomics Shared Resource, Center for Personalized Medicine, Roswell Park Cancer Institute, Buffalo, NY

4 Bioinformatics Core, Biostatistics, Roswell Park Cancer Institute, Buffalo, NY

Correspondence to:

Dr. Vita Golubovskaya, e-mail: [email protected]

Dr. William G. Cance, e-mail: [email protected]

Received: June 18, 2014     Accepted: August 22, 2014     Published: August 25, 2014


Focal adhesion kinase (FAK) is up-regulated in thyroid cancer and small molecule FAK scaffolding inhibitor, Y15, was shown to decrease cancer growth in vitro and in vivo. We sought to test the effectiveness of Y15 in thyroid cancer cell lines, profile gene expression with Y15 compared with clinical trial FAK inhibitor PF-04554878, and use Y15 in novel drug combinations. Cell viability was decreased in a dose dependent manner in four thyroid cancer cell lines with Y15 and with higher doses in PF-04554878. Y397 FAK and total FAK were decreased with Y15 and decreased less with PF-04554878. Detachment and necrosis were increased in a dose-dependent manner in all cell lines with Y15. Clonogenicity was decreased in a dose-dependent manner for both Y15 and PF-04554878. We compared gene profiles between papillary thyroid cell lines, TPC1, BCPAP and K1, and 380, 109, and 74 genes were significantly >2-fold changed with Y15 treatment, respectively. Common up-regulated genes were involved in apoptosis, cell cycle, transcription and heat shock; down-regulated genes were involved in cell cycle, cell-to-cell interactions, and cancer stem cell markers. We also compared gene profiles of TT cells treated with Y15 versus PF-04554878. Y15 caused 144 genes to change over 4 fold and PF-04554878 caused 208 gene changes >4-fold (p<0.05). Among genes changed 4 fold, 11 were shared between the treatments, including those involved in metabolism, cell cycle, migration and transcription. Y15 demonstrated synergy with PF-04554878 in TT cells and also synergy with Cabozantinib, Sorafenib, Pazopanib, and strong synergy with Sunitinib in resistant K1 cells. This report revealed the biological effect of Y15 inhibitor, detected the unique and common gene signature profiles in response to Y15 in 4 different thyroid cancer cell lines, demonstrated differential response changes with Y15 and PF-04554878 treatment, and showed the synergy of Y15 with PF-04554878, Cabozantinib, Sorafenib, Pazopanib, and Sunitinib.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 2381